Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Trial details
- Registry ID
- NCT05257408
- Drugs studied
- Nab-paclitaxel 100 mg/m^2, Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg, Relacorilant 150 mg once daily (QD)